

Nicholas J Short

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3824064/publications.pdf>

Version: 2024-02-01

465
papers

19,910
citations

10956

71
h-index

17055

122
g-index

470
all docs

470
docs citations

470
times ranked

13686
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1090-1098.	2.0	550
2	Acute myeloid leukaemia. <i>Lancet</i> , The, 2018, 392, 593-606.	6.3	512
3	Inotuzumab ozogamicin, an anti-CD22 α chimeric antibody conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 403-411.	5.1	401
4	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
5	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	7.7	380
6	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4422-4429.	0.6	336
7	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	2.0	336
8	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	2.8	313
9	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012, 119, 1981-1987.	0.6	298
10	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017, 129, 572-581.	0.6	285
11	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	2.0	265
12	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	6.9	257
13	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. <i>Blood</i> , 2016, 127, 1863-1869.	0.6	253
14	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	5.1	245
15	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010, 116, 3830-3834.	2.0	241
16	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2521-2527.	0.8	232
17	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	0.8	231
18	Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. <i>American Journal of Hematology</i> , 2020, 95, 691-709.	2.0	229

#	ARTICLE	IF	CITATIONS
19	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	0.8	227
20	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	0.6	214
21	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <i>Cancer Discovery</i> , 2020, 10, 506-525.	7.7	212
22	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-CVATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	2.0	210
23	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1890.	3.4	207
24	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020, 396, 1885-1894.	6.3	206
25	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology,the</i> , 2020, 7, e724-e736.	2.2	201
26	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 2517-2528.	2.0	200
27	<i><i>TP53</i></i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	2.0	200
28	Impact of complete molecular response on survival in patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 504-507.	0.6	194
29	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018, 19, 240-248.	5.1	192
30	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	1.7	191
31	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology,the</i> , 2018, 5, e618-e627.	2.2	190
32	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 4158-4164.	2.0	181
33	New Oral Anticoagulants and the Cancer Patient. <i>Oncologist</i> , 2014, 19, 82-93.	1.9	180
34	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. <i>Blood</i> , 2007, 109, 3214-3218.	0.6	174
35	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
36	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 2204-2210.	0.8	158

#	ARTICLE	IF	CITATIONS
37	Hyper-CD34+ CD38+ CD123+ acute lymphoblastic leukemia versus hyper-CD34+ CD38+ CD123+ acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	2.0	156
38	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
39	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017, 130, 1514-1522.	0.6	151
40	Monoclonal antibodies in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4010-4016.	0.6	144
41	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. <i>Leukemia</i> , 2020, 34, 682-696.	3.3	140
42	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2007, 110, 2991-2995.	0.6	138
43	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	7.7	137
44	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011, 118, 4541-4546.	0.6	133
45	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 1025-1036.	5.1	129
46	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.2	127
47	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013, 121, 4867-4874.	0.6	124
48	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	3.4	124
49	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015, 121, 556-561.	2.0	122
50	Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. <i>Cancer</i> , 2008, 113, 985-994.	2.0	120
51	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
52	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689.	2.5	105
53	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. <i>Cancer</i> , 2010, 116, 5568-5574.	2.0	104
54	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 392-400.	1.2	102

#	ARTICLE	IF	CITATIONS
55	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	6.9	100
56	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	2.0	99
57	Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, 2548-2553.	0.8	96
58	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	2.0	95
59	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071982731.	1.1	93
60	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	1.7	91
61	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. <i>Blood</i> , 2011, 118, 4690-4693.	0.6	88
62	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	2.0	88
63	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	2.0	87
64	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	2.2	86
65	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
66	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	0.8	86
67	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85
68	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	2.2	84
69	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	2.5	83
70	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561.	2.2	81
71	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. <i>Haematologica</i> , 2021, 106, 894-898.	1.7	80
72	Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80

#	ARTICLE	IF	CITATIONS
73	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	2.0	79
74	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. <i>Haematologica</i> , 2020, 105, 697-707.	1.7	78
75	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 2290-2300.	2.0	77
76	Therapeutic implications of menin inhibition in acute leukemias. <i>Leukemia</i> , 2021, 35, 2482-2495.	3.3	76
77	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
78	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.2	71
79	Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. <i>Journal of Clinical Oncology</i> , 2016, 34, 7008-7008.	0.8	71
80	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory T-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70
81	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.4	69
82	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 1413.	3.4	69
83	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	2.0	69
84	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	2.0	68
85	Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. <i>American Journal of Hematology</i> , 2022, 97, 1236-1256.	2.0	68
86	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66
87	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	2.2	65
88	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	0.6	65
89	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. <i>Blood Cancer Journal</i> , 2019, 9, 7.	2.8	64
90	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	2.0	63

#	ARTICLE	IF	CITATIONS
91	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
92	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	1.3	63
93	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGO) as frontline regimen in patients with core binding factor acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2014, 89, 964-968.	2.0	62
94	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2607.	5.8	61
95	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 139-145.	0.2	60
96	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
97	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 282-287.	2.0	58
98	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	0.7	57
99	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
100	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	2.0	54
101	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	0.7	53
102	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. <i>Scientific Reports</i> , 2017, 7, 11253.	1.6	52
103	Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. <i>American Journal of Hematology</i> , 2021, 96, 650-658.	2.0	52
104	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	2.0	51
105	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Current Treatment Options in Oncology</i> , 2019, 20, 4.	1.3	50
106	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	2.0	50
107	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
108	Chronic myeloid leukemia: First-line drug of choice. <i>American Journal of Hematology</i> , 2016, 91, 59-66.	2.0	49

#	ARTICLE	IF	CITATIONS
109	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
110	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48
111	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	2.0	46
112	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>American Journal of Hematology</i> , 2016, 91, 227-232.	2.0	46
113	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2013, 88, 831-837.	2.0	43
114	The role of clofarabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 688-698.	0.6	43
115	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
116	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	2.0	42
117	Poor outcomes associated with +der(22)t(9;22) and 9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41
118	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
119	Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis. <i>Cancer Cell International</i> , 2005, 5, 23.	1.8	40
120	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382.	2.0	40
121	Recent Advances in Managing Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 330-342.	1.8	40
122	Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. <i>Blood</i> , 2020, 136, 1786-1789.	0.6	40
123	Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	2.0	40
124	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	2.0	39
125	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 257-265.	0.2	39
126	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. <i>American Journal of Hematology</i> , 2018, 93, 286-295.	2.0	38

#	ARTICLE	IF	CITATIONS
127	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
128	Religion and Spirituality: A Barrier and a Bridge in the Everyday Professional Work of Pediatric Physicians. <i>Social Problems</i> , 2009, 56, 702-721.	2.0	37
129	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	2.0	37
130	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. <i>Haematologica</i> , 2019, 104, 1532-1541.	1.7	37
131	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	2.5	37
132	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	3.3	37
133	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 691-700.	3.3	37
134	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	2.5	37
135	A phase 1 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011, 117, 1236-1244.	2.0	36
136	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	2.0	35
137	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
138	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 244-251.	0.2	34
139	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	2.8	34
140	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	2.0	34
141	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	2.0	34
142	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	0.6	34
143	Prognostic factors for progression in patients with Philadelphia chromosome positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	2.0	33
144	Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 137.	6.9	33

#	ARTICLE	IF	CITATIONS
145	A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 696-696.	0.6	33
146	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	2.0	33
147	Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
148	Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. <i>Current Oncology Reports</i> , 2017, 19, 6.	1.8	32
149	Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E114-E117.	2.0	32
150	Significance of recurrence of minimal residual disease detected by multiparameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	2.0	32
151	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
152	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.4	32
153	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32
154	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	2.0	31
155	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	0.6	31
156	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
157	Impact of comorbidities by ACE27 in the revised IPSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014, 89, 509-516.	2.0	30
158	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	2.0	30
159	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	0.6	30
160	Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens. <i>JAMA Oncology</i> , 2022, 8, 1340.	3.4	30
161	Intra-Abdominal Splenosis Mimicking Metastatic Cancer. <i>American Journal of the Medical Sciences</i> , 2011, 341, 246-249.	0.4	29
162	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	0.8	29

#	ARTICLE	IF	CITATIONS
163	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	2.5	29
164	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. <i>Genes</i> , 2020, 11, 649.	1.0	29
165	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	3.3	29
166	Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesis. <i>Cancer Cell International</i> , 2005, 5, 12.	1.8	28
167	Verification of simple hydration/dehydration methods to characterize multiple water compartments on Tendon Type 1 Collagen. <i>Cell Biology International</i> , 2007, 31, 531-539.	1.4	28
168	Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S25-S29.	0.2	28
169	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	2.0	28
170	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i> mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	1.2	28
171	The clinical development of antibody “drug conjugates” lessons from leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 418-433.	12.5	28
172	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.2	28
173	Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 193-200.	0.7	27
174	First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. <i>Leukemia and Lymphoma</i> , 2018, 59, 1523-1538.	0.6	27
175	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	2.2	27
176	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	2.0	26
177	Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 87-97.e5.	0.2	26
178	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
179	The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 253-261.	1.1	25
180	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 369.	1.3	25

#	ARTICLE	IF	CITATIONS
181	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
182	Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091002.	1.1	25
183	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	2.0	25
184	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1670-1677.	2.5	24
185	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24
186	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	2.0	24
187	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	2.5	24
188	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	0.6	24
189	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	2.0	23
190	<p>Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 23-34.	3.0	23
191	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	2.0	23
192	Muehrcke's Lines. <i>American Journal of Medicine</i> , 2010, 123, 991-992.	0.6	22
193	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2018, 25, 146-153.	1.2	22
194	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	1.2	21
195	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	2.9	21
196	Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 3807-3807.	0.6	21
197	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 302-306.	0.2	20
198	SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 439-446.	0.2	20

#	ARTICLE	IF	CITATIONS
199	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	2.0	20
200	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	2.8	20
201	Clonal hematopoiesis of indeterminate potential associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	2.0	19
202	Decitabine and venetoclax for IDH1/2 mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
203	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	6.9	19
204	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	0.6	19
205	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	0.6	19
206	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 83-83.	0.6	19
207	Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2298-2298.	0.6	19
208	Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 216-223.	0.3	19
209	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2.	0.2	18
210	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	2.0	18
211	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984949.	1.1	18
212	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	6.9	18
213	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7001-7001.	0.8	18
214	Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. <i>Blood</i> , 2020, 136, 19-20.	0.6	18
215	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7013-7013.	0.8	18
216	Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. <i>Current Oncology Reports</i> , 2022, 24, 427-436.	1.8	18

#	ARTICLE	IF	CITATIONS
217	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	2.0	17
218	Factors associated with risk of central nervous system relapse in patients with non–core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 924-928.	2.0	17
219	Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 574-578.	1.8	17
220	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1–mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	2.0	17
221	Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. <i>Blood Cancer Journal</i> , 2020, 10, 47.	2.8	17
222	An effective chemotherapy–free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	2.0	17
223	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. <i>Blood</i> , 2018, 132, 553-553.	0.6	17
224	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	0.6	17
225	Myeloid neoplasms after breast cancer: therapy-related–not an independent poor prognostic factor. <i>Leukemia and Lymphoma</i> , 2015, 56, 1012-1019.	0.6	16
226	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 813-820.	0.6	16
227	Outcome of adults with relapsed/refractory T–cell acute lymphoblastic leukemia or lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E245-E247.	2.0	16
228	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	3.2	16
229	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	3.3	16
230	Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 91-99.	1.2	15
231	Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. <i>Journal of Clinical Pathology</i> , 2019, 72, 251-257.	1.0	15
232	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper–CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	2.0	15
233	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy. <i>Blood Advances</i> , 2021, 5, 4569-4574.	2.5	15
234	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	0.6	15

#	ARTICLE	IF	CITATIONS
235	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	2.0	15
236	Fludarabine, cyclophosphamide, and multipleâ€dose rituximab as frontline therapy for chronic lymphocytic leukemia. <i>Cancer</i> , 2015, 121, 3869-3876.	2.0	14
237	Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 115-118.	0.6	14
238	Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2021, 39, 2535-2538.	0.8	14
239	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2018, 132, 32-32.	0.6	14
240	Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 15-17.	0.6	14
241	Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (â‰¥65 yrs) with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1639-1639.	0.6	14
242	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 351-358.	2.0	13
243	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1709-1717.	1.7	13
244	Emergence of BCRâ€ABL1 Fusion in AML Postâ€FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance â€ A Case Series. <i>Frontiers in Oncology</i> , 2020, 10, 588876.	1.3	13
245	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	2.0	13
246	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. <i>Blood</i> , 2018, 132, 2702-2702.	0.6	13
247	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 9-11.	0.6	13
248	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	0.6	13
249	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12.	6.9	13
250	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. <i>American Journal of Hematology</i> , 2016, 91, 1221-1226.	2.0	12
251	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	0.8	12
252	Survivorship in AML â€ a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <i>Leukemia and Lymphoma</i> , 2020, 61, 3120-3127.	0.6	12

#	ARTICLE	IF	CITATIONS
253	Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. American Journal of Hematology, 2021, 96, E379-E383.	2.0	12
254	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2018, 132, 36-36.	0.6	12
255	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2019, 134, 823-823.	0.6	12
256	Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood, 2020, 136, 33-36.	0.6	12
257	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. Journal of Clinical Oncology, 2018, 36, 7041-7041.	0.8	12
258	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	2.0	12
259	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	0.6	12
260	A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 442-444.	1.2	11
261	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416.	2.0	11
262	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647.	0.6	11
263	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 1641-1641.	0.6	11
264	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood, 2019, 134, 3806-3806.	0.6	11
265	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 588-588.	0.6	11
266	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, .	2.0	11
267	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American Journal of Hematology, 2019, 94, 74-79.	2.0	10
268	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leukemia and Lymphoma, 2020, 61, 2012-2015.	0.6	10
269	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e871-e882.	0.2	10
270	Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. Therapeutic Advances in Hematology, 2020, 11, 204062072093061.	1.1	10

#	ARTICLE	IF	CITATIONS
271	Phase 2 study of hyper-ECMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	2.0	10
272	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
273	Hyper-ECVAD plus ofatumumab versus hyper-ECVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	2.0	10
274	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428.	2.0	10
275	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19.	0.6	10
276	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. <i>Acta Haematologica</i> , 2021, 144, 285-292.	0.7	10
277	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
278	Endothelial cell pseudopods and angiogenesis of breast cancer tumors. <i>Cancer Cell International</i> , 2005, 5, 17.	1.8	9
279	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF- κ B activation. <i>Leukemia Research</i> , 2018, 73, 78-85.	0.4	9
280	Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228.	2.0	9
281	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
282	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3810-3810.	0.6	9
283	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 461-461.	0.6	9
284	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	3.3	9
285	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 7-16.	1.2	9
286	Safe alternative cancer therapy using electromagnetic fields. <i>The Environmentalist</i> , 2007, 27, 453-456.	0.7	8
287	Clinical characteristics and outcomes of previously untreated patients with adult onset acute lymphoblastic leukemia and lymphoblastic lymphoma with hyper-ECVAD based regimens. <i>American Journal of Hematology</i> , 2017, 92, E595-E597.	2.0	8
288	Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7010-7010.	0.8	8

#	ARTICLE	IF	CITATIONS
289	When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era. <i>Journal of Clinical Oncology</i> , 2021, 39, 3104-3108.	0.8	8
290	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	0.6	8
291	Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 20-22.	0.6	8
292	Hyperleukocytosis and leukostasis in acute and chronic leukemias. <i>Leukemia and Lymphoma</i> , 2022, 63, 1780-1791.	0.6	8
293	Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. <i>Lancet Haematology</i> , 2022, 9, e535-e545.	2.2	8
294	The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. <i>Expert Review of Hematology</i> , 2016, 9, 529-534.	1.0	7
295	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (μ) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. <i>Blood</i> , 2018, 132, 663-663.	0.6	7
296	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
297	"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions" Treatment of ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 301-310.	0.2	6
298	Antibody based therapy in relapsed acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101225.	0.7	6
299	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. <i>Leukemia and Lymphoma</i> , 2021, 62, 224-228.	0.6	6
300	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. <i>Blood</i> , 2018, 132, 84-84.	0.6	6
301	The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. <i>Blood</i> , 2020, 136, 28-29.	0.6	6
302	Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 3801-3801.	0.6	6
303	Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 2783-2783.	0.6	6
304	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	1.7	6
305	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1176-1184.	1.1	6
306	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10^{-4} and higher. <i>American Journal of Hematology</i> , 2022, 97, 1135-1141.	2.0	6

#	ARTICLE	IF	CITATIONS
307	Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?. <i>European Journal of Haematology</i> , 2018, 101, 418-420.	1.1	5
308	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	2.0	5
309	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	2.8	5
310	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	1.3	5
311	Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. <i>Blood Advances</i> , 2021, 5, 3913-3918.	2.5	5
312	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 61-66.	0.2	5
313	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4017-4017.	0.6	5
314	Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3819-3819.	0.6	5
315	Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML. <i>Blood</i> , 2019, 134, 1428-1428.	0.6	5
316	Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 7-9.	0.6	5
317	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. <i>Blood</i> , 2020, 136, 26-28.	0.6	5
318	Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7013-7013.	0.8	5
319	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 29-36.	1.0	5
320	Characterization of water of hydration fractions in rabbit skeletal muscle with age and time of post-mortem by centrifugal dehydration force and rehydration methods. <i>Cell Biology International</i> , 2008, 32, 1337-1343.	1.4	4
321	Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 385-389.	2.0	4
322	Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 2508-2510.	0.6	4
323	10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply. <i>Lancet Haematology</i> , 2019, 6, e178.	2.2	4
324	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , 2019, 94, E188-E190.	2.0	4

#	ARTICLE	IF	CITATIONS
325	Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2021, 39, e19019-e19019.	0.8	4
326	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Current Oncology Reports, 2021, 23, 95.	1.8	4
327	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood, 2018, 132, 34-34.	0.6	4
328	Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 1296-1296.	0.6	4
329	Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). Blood, 2019, 134, 1299-1299.	0.6	4
330	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2020, 136, 11-12.	0.6	4
331	Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood, 2020, 136, 36-39.	0.6	4
332	AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis. Blood, 2020, 136, 31-32.	0.6	4
333	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	2.0	4
334	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. American Journal of Hematology, 2022, 97, .	2.0	4
335	A simple centrifugal dehydration force method to characterize water compartments in fresh and post-mortem fish muscle. Cell Biology International, 2007, 31, 516-520.	1.4	3
336	Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101226.	0.7	3
337	The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 63-65.	0.2	3
338	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. Acta Haematologica, 2021, 144, 585-590.	0.7	3
339	A new era in the treatment of acute lymphoblastic leukemia. Blood, 2021, 137, 1563-1564.	0.6	3
340	<sc>FLT3</sc> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <sc>Acute Myeloid Leukemia</sc> with very low <sc>FLT3</sc> allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	2.0	3
341	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. Blood, 2019, 134, 1344-1344.	0.6	3
342	Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO. Blood, 2019, 134, 3851-3851.	0.6	3

#	ARTICLE	IF	CITATIONS
343	Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. <i>Blood</i> , 2019, 134, 738-738.	0.6	3
344	A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy. <i>Blood</i> , 2020, 136, 34-35.	0.6	3
345	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. <i>Blood</i> , 2020, 136, 30-33.	0.6	3
346	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. <i>Blood</i> , 2020, 136, 46-48.	0.6	3
347	Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 1606-1606.	0.6	3
348	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2016, 128, 226-226.	0.6	3
349	Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7029-7029.	0.8	3
350	Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7036-7036.	0.8	3
351	Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7033-7033.	0.8	3
352	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 2577-2577.	0.6	3
353	Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1233-1233.	0.6	3
354	Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacitidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 367-367.	0.6	3
355	Outcomes of <i>De Novo</i> Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. <i>Blood</i> , 2020, 136, 11-13.	0.6	3
356	Indiscriminate Testing for Heparin-Induced Thrombocytopenia. <i>JAMA Internal Medicine</i> , 2016, 176, 592.	2.6	2
357	Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S256-S257.	0.2	2
358	Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S265.	0.2	2
359	Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S52-S53.	0.2	2
360	The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making—Reply. <i>JAMA Oncology</i> , 2021, 7, 784.	3.4	2

#	ARTICLE	IF	CITATIONS
361	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	2
362	Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1548-1548.	0.6	2
363	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. <i>Blood</i> , 2018, 132, 3983-3983.	0.6	2
364	Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. <i>Blood</i> , 2018, 132, 5212-5212.	0.6	2
365	Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. <i>Blood</i> , 2019, 134, 735-735.	0.6	2
366	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1715-1715.	0.6	2
367	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582.	0.6	2
368	Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-25.	0.6	2
369	Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
370	Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.. <i>Blood</i> , 2009, 114, 2775-2775.	0.6	2
371	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. <i>Blood</i> , 2016, 128, 3975-3975.	0.6	2
372	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 757-757.	0.6	2
373	Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7014-7014.	0.8	2
374	Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7051-7051.	0.8	2
375	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline "chemotherapy-free"™ therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 672-675.	0.6	2
376	Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies. <i>Blood</i> , 2020, 136, 22-24.	0.6	2
377	Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
378	Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials. <i>Blood</i> , 2020, 136, 2-4.	0.6	2

#	ARTICLE	IF	CITATIONS
379	Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4935-4936.	2.0	1
380	Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S257-S258.	0.2	1
381	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S193-S194.	0.2	1
382	Management of Older Patients with Acute Lymphocytic Leukemia – Novel Treatment Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S30-S31.	0.2	1
383	Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. <i>Blood</i> , 2018, 132, 3689-3689.	0.6	1
384	Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2018, 132, 2659-2659.	0.6	1
385	Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis. <i>Blood</i> , 2019, 134, 2592-2592.	0.6	1
386	Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). <i>Blood</i> , 2019, 134, 1447-1447.	0.6	1
387	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. <i>Blood</i> , 2020, 136, 38-40.	0.6	1
388	Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories. <i>Blood</i> , 2020, 136, 8-9.	0.6	1
389	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 2877-2877.	0.6	1
390	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. <i>Blood</i> , 2016, 128, 2916-2916.	0.6	1
391	Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7025-7025.	0.8	1
392	Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7042-7042.	0.8	1
393	Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7066-7066.	0.8	1
394	Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3985-3985.	0.6	1
395	Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). <i>Blood</i> , 2019, 134, 2578-2578.	0.6	1
396	Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 38-39.	0.6	1

#	ARTICLE	IF	CITATIONS
397	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 23-25.	0.6	1
398	A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S264-S265.	0.2	0
399	Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S266.	0.2	0
400	Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S255-S256.	0.2	0
401	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 347-356.	1.1	0
402	Risk of Infection with Ibrutinib in Patients with Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Phase III Randomized Controlled Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S215.	0.2	0
403	Prognostic Impact of Full Hematologic Recovery and Achievement of Measurable Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) After First Salvage Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S218-S219.	0.2	0
404	Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S181.	0.2	0
405	Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186-S187.	0.2	0
406	The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180.	0.2	0
407	Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180-S181.	0.2	0
408	Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S185.	0.2	0
409	Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186.	0.2	0
410	Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patient. <i>American Journal of Hematology</i> , 2020, 95, 1117-1120.	2.0	0
411	Characteristics and outcomes of patients diagnosed with DNMT3A mutated acute myeloblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19018-e19018.	0.8	0
412	Hyper-CVAD in 2021: Lessons Learned and New Approaches. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S82-S84.	0.2	0
413	Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18045-e18045.	0.8	0
414	Persistence of Cytogenetic Abnormalities at Complete Remission Is Not Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1416-1416.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7038-7038.	0.8	0
416	Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7034-7034.	0.8	0
417	Quality and cost comparison of powered versus manual bone marrow biopsy devices at a large U.S. cancer center.. Journal of Clinical Oncology, 2016, 34, e18283-e18283.	0.8	0
418	Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7035-7035.	0.8	0
419	Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2016, 128, 1067-1067.	0.6	0
420	Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood, 2016, 128, 1737-1737.	0.6	0
421	Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma. Blood, 2016, 128, 5150-5150.	0.6	0
422	Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. Blood, 2016, 128, 3977-3977.	0.6	0
423	A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood, 2016, 128, 4328-4328.	0.6	0
424	Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study.. Journal of Clinical Oncology, 2017, 35, 7037-7037.	0.8	0
425	Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.. Journal of Clinical Oncology, 2018, 36, 7064-7064.	0.8	0
426	Association of early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) with high response rates and long duration of response.. Journal of Clinical Oncology, 2018, 36, 7001-7001.	0.8	0
427	Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period.. Journal of Clinical Oncology, 2018, 36, 7022-7022.	0.8	0
428	Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.. Journal of Clinical Oncology, 2018, 36, 7053-7053.	0.8	0
429	Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 1814-1814.	0.6	0
430	Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood, 2018, 132, 3976-3976.	0.6	0
431	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 4359-4359.	0.6	0
432	Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials. Blood, 2018, 132, 1869-1869.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). <i>Blood</i> , 2018, 132, 2664-2664.	0.6	0
434	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. <i>Blood</i> , 2018, 132, 1417-1417.	0.6	0
435	Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2695-2695.	0.6	0
436	Risk of Infection with Ibrutinib in Patients with B-Cell Malignancies: A Meta-Analysis of Phase III Randomized Controlled Trials. <i>Blood</i> , 2018, 132, 2871-2871.	0.6	0
437	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). <i>Blood</i> , 2019, 134, 287-287.	0.6	0
438	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. <i>Blood</i> , 2019, 134, 1297-1297.	0.6	0
439	Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. <i>Blood</i> , 2019, 134, 2753-2753.	0.6	0
440	The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). <i>Blood</i> , 2019, 134, 3815-3815.	0.6	0
441	Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 4252-4252.	0.6	0
442	Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2019, 134, 3834-3834.	0.6	0
443	Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant. <i>Blood</i> , 2019, 134, 5186-5186.	0.6	0
444	Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 169-184.	0.2	0
445	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 205-218.	0.2	0
446	Management of Relapsed/Refractory Acute Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021, , 89-109.	0.2	0
447	Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 21-23.	0.6	0
448	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. <i>Blood</i> , 2020, 136, 40-42.	0.6	0
449	Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2020, 136, 54-56.	0.6	0
450	Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. <i>Blood</i> , 2020, 136, 16-17.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. <i>Blood</i> , 2020, 136, 46-48.	0.6	0
452	Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
453	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. <i>Blood</i> , 2020, 136, 2-4.	0.6	0
454	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
455	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
456	Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
457	Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
458	Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvt-Inotuzumab Ozogamicin with or without Blinatumomab Regimens. <i>Blood</i> , 2020, 136, 41-43.	0.6	0
459	Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
460	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
461	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
462	Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2020, 136, 3-4.	0.6	0
463	Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
464	Imatinib: high dose versus standard dose. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 812-4.	0.3	0
465	Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 892-894.	0.3	0